The objectives of the Virginia Mason CCOP are as follows: A. To increase accrual to CCOP treatment protocols by at least 10 per year, achieving a total of over 100 patients per year by 1998. B. To continue the impressive in accrual to cancer control protocols, achieving more than 100 credits per year by 1998. We will specifically focus on the two major cancer prevention trials, i.e., the tamoxifen breast cancer and the Proscar prostatic cancer prevention trials. C. To continue to bring the advantages of state-of-the-art cancer treatment and cancer control trials to patients in metropolitan Seattle and in smaller communities in Western Washington and Alaska by strengthening and expanding both the core institution participation in the activities of the CCOP and our relationship with the component institutions, Valley Medical Center (Renton, WA), Evergreen Medical Center (Kirkland, WA), Olympic Memorial Hospital (Pt. Angeles, WA), Providence and Humana Hospitals (Anchorage, AK), and the physicians who practice in these hospitals. D. To seek out and develop relationships with other medical institutions in the Pacific Northwest and Alaska, hoping to expand the number of component institutions committed to the goals and directions of the VM CCOP. E. To pursue the possibility for including the unique minority population, Alaska Native Americans, in the cancer treatment and cancer control activities of the CCOP program. F. To contribute as much as possible to the scientific and administrative affairs of each research base by active participation in their meetings and committee structures.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035192-12
Application #
2088867
Study Section
Special Emphasis Panel (SRC (74))
Project Start
1983-09-01
Project End
1997-05-31
Budget Start
1995-08-01
Budget End
1996-05-31
Support Year
12
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Benaroya Research Institute at Virginia Mason
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98101
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Mata, Douglas A; Groshen, Susan; Von Rundstedt, Friedrich-Carl et al. (2015) Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol 111:923-8
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
von Rundstedt, Friedrich-Carl; Mata, Douglas A; Groshen, Susan et al. (2015) Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int 116:44-9
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7

Showing the most recent 10 out of 131 publications